New Antifungals for Vulvovaginal Candidiasis: What Is Their Role?
Jack D. Sobel
Abstract
New antifungals, ibrexafungerp and oteseconazole, are now available for treatment of vulvovaginal candidiasis. Both have novel antimicrobial and pharmacokinetic properties and advantages over fluconazole, although comparative trials have involved only placebo. In the absence of allergy, intolerance, and resistance, it is unclear whether these antifungals will replace fluconazole.
Topics & Concepts
FluconazoleMedicineVulvovaginal CandidiasisDermatologyInvasive candidiasisPlaceboMycosisAntifungalIntensive care medicineImmunologyPathologyAlternative medicineAntifungal resistance and susceptibilityNail Diseases and TreatmentsHerbal Medicine Research Studies